Covid: Gimbe, in the Marche -1.9% new cases in one week – Marche

Covid: Gimbe, in the Marche -1.9% new cases in one week – Marche
Covid: Gimbe, in the Marche -1.9% new cases in one week – Marche
CopyAMP code


Incidence per 100,000 inhabitants drops to 275.6

(ANSA) – ANCONA, JAN 09 – In the Marche region, in the week of December 30-January 5, there was an improvement in the incidence of coronavirus positives per 100,000 inhabitants (275.6) and there was a decrease in new cases (- 1.9%) compared to the previous week. It emerges from the weekly monitoring of the Gimbe Foundation. At the provincial level, Ascoli Piceno leads the ranking with an incidence of 364 (+0.5% compared to the previous week); then Macerata (331; +4.1%), Fermo (291; -14.5%), Ancona (224; +1.7%), Pesaro and Urbino (174; -11.8%).

On the hospitalization front, the Marches are above the national average for beds in the medical area occupied by Covid patients (16.3%) while the number of beds in intensive care is below the national average (2.2%). The percentage of the over 5-year-old population who did not receive any dose of vaccine is 12.9% (Italian average 10.7%) to which must be added the temporarily protected population over 5-year-olds, as they recovered less from Covid-19 of 180 days, equal to 1.9%; the percentage of the over 5 year old population who did not receive the third dose of the vaccine is 12.1% (Italian average 12%) to which must be added the over 5 year old population healed for less than 120 days, who cannot receive the third immediate dose, equal to 4.4%. The vaccination coverage rate with the fourth dose is 22.1% (Italian average 29.7%).

Finally, the population aged 5-11 who completed the vaccination cycle is 20.7% (Italian average 35.3%) to which a further 2% (Italian average 3.2%) must be added with only the first dose. (HANDLE).

REPRODUCTION RESERVED © Copyright ANSA

CopyAMP code.

Get the embed code



The article is in Italian

Tags: Covid Gimbe Marche cases week Marche

NEXT Covid-19 and intensive care: the vaccine reduces the risk of death even in vaccinated people affected by serious infections